TY - JOUR
T1 - Clinical spectrum of individuals with de novo EBF3 variants or deletions
AU - Nishi, Eriko
AU - Uehara, Tomoko
AU - Yanagi, Kumiko
AU - Hasegawa, Yuiko
AU - Ueda, Kimiko
AU - Kaname, Tadashi
AU - Yamamoto, Toshiyuki
AU - Kosaki, Kenjiro
AU - Okamoto, Nobuhiko
N1 - Funding Information:
The authors are deeply grateful to the patients and their families. This study was supported by the Practical Research Project for Rare/Intractable Diseases from Japan Agency for Medical Research and development (AMED), a Grant‐in‐Aid for Scientific Research from Health Labor Sciences Research Grants from the Ministry of Health, Labor and Welfare, Japan, in part by grants of the Initiative on Rare and Undiagnosed Diseases (IRUD) (18ek0109301, 19ek0109301h0002, 20ek0109301h0003) from AMED, and JSPS KAKENHI Grant Number JP18K07863 (Tadashi Kaname), 18 K07803 (Toshiyuki Yamamoto) from Japan Society for the Promotion of Science. The authors thank Barry Patel, PhD, from Edanz Group ( https://en-author-services.edanz.com/ac ) for editing a draft of this manuscript.
Funding Information:
Scientific Research from Health Labor Sciences Research Grants from the Ministry of Health, Labor and Welfare, Japan; the Initiative on Rare and Undiagnosed Diseases (IRUD) from Japan Agency for Medical Research and Development, Grant/Award Numbers: 18ek0109301, 19ek0109301h0002, 20ek0109301h0003; Japan Society for the Promotion of Science, Grant/Award Numbers: 18K07803, JP18K07863; The Practical Research Project for Rare/ Intractable Diseases from Japan Agency for Medical Research and development Funding information
Publisher Copyright:
© 2021 Wiley Periodicals LLC.
PY - 2021/10
Y1 - 2021/10
N2 - Hypotonia, ataxia and delayed development syndrome (HADDS) (MIM#617330) is a neurodevelopmental disorder caused by heterozygous pathogenic variants in EBF3 (MIM; 607,407), which is located on chromosome 10q26, and was first reported in 2017. To date, missense, nonsense and frameshift variants have been reported as causes of HADDS, and EBF3 pathogenic variants have been predicted to result in nonsense-mediated mRNA decay and haploinsufficiency. It was also reported that total deletion of EBF3 associated with a 10q26.3 microdeletion also causes HADDS symptoms, supporting the concept that HADDS results from haploinsufficiency of EBF3. Here, we report eight unrelated individuals with heterozygous pathogenic variants of EBF3 or haploinsufficiency of EBF3 due to 10q26 deletion, who exhibit clinical findings including craniofacial features of HADDS. In a detailed examination of clinical manifestations in this study, revealed that neurogenic bladder was diagnosed in infancy (the median 6.5 months), was more frequent than previously reported, and required cystostomy in all but one case. For psychomotor delay, it was also found that their motor/skills values were significantly lower than their cognition/adaptation values (p = 0.0016; paired t-test). Therefore, that HADDS is a recognizable syndrome that shares its characteristic facial features, and that neurogenic bladder diagnosed in infancy and psychomotor delay with marked delay in motor/skills are noteworthy findings in the diagnosis and management of individuals with HADDS.
AB - Hypotonia, ataxia and delayed development syndrome (HADDS) (MIM#617330) is a neurodevelopmental disorder caused by heterozygous pathogenic variants in EBF3 (MIM; 607,407), which is located on chromosome 10q26, and was first reported in 2017. To date, missense, nonsense and frameshift variants have been reported as causes of HADDS, and EBF3 pathogenic variants have been predicted to result in nonsense-mediated mRNA decay and haploinsufficiency. It was also reported that total deletion of EBF3 associated with a 10q26.3 microdeletion also causes HADDS symptoms, supporting the concept that HADDS results from haploinsufficiency of EBF3. Here, we report eight unrelated individuals with heterozygous pathogenic variants of EBF3 or haploinsufficiency of EBF3 due to 10q26 deletion, who exhibit clinical findings including craniofacial features of HADDS. In a detailed examination of clinical manifestations in this study, revealed that neurogenic bladder was diagnosed in infancy (the median 6.5 months), was more frequent than previously reported, and required cystostomy in all but one case. For psychomotor delay, it was also found that their motor/skills values were significantly lower than their cognition/adaptation values (p = 0.0016; paired t-test). Therefore, that HADDS is a recognizable syndrome that shares its characteristic facial features, and that neurogenic bladder diagnosed in infancy and psychomotor delay with marked delay in motor/skills are noteworthy findings in the diagnosis and management of individuals with HADDS.
KW - 10q26 deletion
KW - EBF3
KW - HADDS
KW - neurogenic bladder
UR - http://www.scopus.com/inward/record.url?scp=85106737368&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85106737368&partnerID=8YFLogxK
U2 - 10.1002/ajmg.a.62369
DO - 10.1002/ajmg.a.62369
M3 - Article
C2 - 34050706
AN - SCOPUS:85106737368
SN - 1552-4825
VL - 185
SP - 2913
EP - 2921
JO - American Journal of Medical Genetics, Part A
JF - American Journal of Medical Genetics, Part A
IS - 10
ER -